endoxifen

Atossa Therapeutics' low-dose (Z)-endoxifen demonstrated significant tumor shrinkage with a 77.7% reduction in functional tumor volume in women with ER+/HER2- breast cancer during the I-SPY 2 trial.

Atossa Therapeutics has strategically repositioned (Z)-endoxifen to target metastatic breast cancer, addressing a significant unmet medical need where current treatments offer limited durability and substantial side effects.

Atossa Therapeutics has proposed a pioneering Phase 3 clinical study called SMART 2.0 to investigate if oral (Z)-endoxifen can reduce interval breast cancer in high-risk women identified through advanced mammographic screening.

Breast cancer claimed over 650,000 lives globally in 2022, driving urgent research into more effective and less toxic treatment approaches.

Atossa Therapeutics presented Phase 2 EVANGELINE trial data at SABCS 2024, evaluating (Z)-endoxifen for ER+/HER2-negative breast cancer in premenopausal women.